Results 1 to 10 of about 103,266 (261)

A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences [PDF]

Nature, 1986
A biologically active complementary DNA clone of a transforming gene present in a human colon carcinoma contains gene sequences of both tropomyosin and a previously unknown protein tyrosine kinase. The predicted protein (641 amino acids) encoded by this oncogene seems to have been formed by a somatic rearrangement that replaced the extracellular domain
Mariano Barbacid, S H Hughes, Barbacid Mariano   +2 more
exaly   +4 more sources

MOLECULAR RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA AFTER COMPLETE REMISSION: A CASE REPORT AND LITERATURE REVIEW [PDF]

精准医学杂志, 2023
Objective To investigate the molecular biological changes of relapsed acute promyelocytic leukemia (APL), and to provide guidance for the clinical diagnosis and treatment of relapsed APL.
CHEN Junru, WANG Yilin, WANG Lingzhen, JIANG Jian, SUN Yan, LU Yuan
doaj   +1 more source

Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins

Blood Cancer Discovery, 2021
Abstract The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations.
Yasen Maimaitiyiming, Qian Qian Wang, Chang Yang, Yasumitsu Ogra, Yinjun Lou, Clayton A. Smith, Liaqat Hussain, Yi Ming Shao, Jiebo Lin, Jinfeng Liu, Lingfang Wang, Yong Zhu, Haiyan Lou, Yuan Huang, Xiaoxia Li, Kao-Jung Chang, Hao Chen, Hongyan Li, Ying Huang, Eric Tse, Jie Sun, Na Bu, Shih-Hwa Chiou, Yan Fang Zhang, Hao Ying Hua, Li Ya Ma, Ping Huang, Ming Hua Ge, Feng-Lin Cao, Xiaodong Cheng, Hongzhe Sun, Jin Zhou, Vasilis Vasliou, Pengfei Xu, Jie Jin, Mikael Bjorklund, Hong-Hu Zhu, Chih-Hung Hsu, Hua Naranmandura   +38 more
openaire   +2 more sources

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

International Journal of Molecular Sciences, 2023
CD74 is a type II cell surface receptor found to be highly expressed in several hematological and solid cancers, due to its ability to activate pathways associated with tumor cell survival and proliferation. Over the past 16 years, CD74 is emerging as a commonly detected fusion partner in multiple oncogenic fusion proteins.
Jasmine Vargas, Georgios Pantouris
openaire   +2 more sources

The fusion partner specifies the oncogenic potential of NUP98 fusion proteins [PDF]

Leukemia Research, 2013
NUP98 is among the most promiscuously translocated genes in hematological diseases. Among the 28 known fusion partners, there are two categories: homeobox genes and non-homeobox genes. The homeobox fusion partners are well-studied in animal models, resulting in HoxA cluster overexpression and hematological disease.
Saw, J, Curtis, DJ, Hussey, DJ, Dobrovic, A, Aplan, PD, Slape, CI   +5 more
openaire   +5 more sources

Genetic fusions favor tumorigenesis through degron loss in oncogenes

Nature Communications, 2021
Chromosomal rearrangements can generate genetic fusions composed of two distinct gene sequences, many of which have been implicated in tumorigenesis and progression.
Jing Liu, Collin Tokheim, Jonathan D. Lee, Wenjian Gan, Brian J. North, X. Shirley Liu, Pier Paolo Pandolfi, Wenyi Wei   +7 more
doaj   +1 more source

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins [PDF]

Proceedings of the National Academy of Sciences, 2013
Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that ROS1 inhibitors are likely to be effective molecularly targeted therapies in these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib to treat ROS1 fusion-harboring non–small-cell ...
Monika A, Davare, Anna, Saborowski, Christopher A, Eide, Cristina, Tognon, Rebecca L, Smith, Johannes, Elferich, Anupriya, Agarwal, Jeffrey W, Tyner, Ujwal P, Shinde, Scott W, Lowe, Brian J, Druker   +10 more
openaire   +2 more sources

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium [PDF]

Oncogene, 2018
Structural rearrangements of the genome can drive lung tumorigenesis through the generation of fusion genes with oncogenic properties. Advanced genomic approaches have identified the presence of a genetic fusion between fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil 3 (TACC3) in non-small cell lung cancer (NSCLC ...
Sarah A. Best, Cassandra R. Harapas, Ariena Kersbergen, Vivek Rathi, Marie-Liesse Asselin-Labat, Kate D. Sutherland   +5 more
openaire   +3 more sources

Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML

Nature Communications, 2020
The oncogene MLL is frequently translocated in leukemia, resulting in oncogenic fusion proteins. Here, the authors report a temporally controlled mouse model of MLL-ENL driven leukemia AND identify therapeutic targets associated with early MLL-ENL driven
Silvia Basilico, Xiaonan Wang, Alison Kennedy, Konstantinos Tzelepis, George Giotopoulos, Sarah J. Kinston, Pedro M. Quiros, Kim Wong, David J. Adams, Larissa S. Carnevalli, Brian J. P. Huntly, George S. Vassiliou, Fernando J. Calero-Nieto, Berthold Göttgens   +13 more
doaj   +1 more source

The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. [PDF]

PLoS ONE, 2009
This study demonstrates deregulation of polycomb activity by the synovial sarcoma-associated SYT-SSX2 oncogene, also known as SS18-SSX2. Synovial sarcoma is a soft tissue cancer associated with a recurrent t(X:18) translocation event that generates one ...
Roy Barco, Christina B Garcia, Josiane E Eid   +2 more
doaj   +1 more source